Morningstar

GC Biopharma Submits IND Application for Phase 1 Clinical Trial of COVID-19 mRNA Vaccine in Korea

YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) ...
Morningstar

Enveda Advances Third Asset to the Clinic With US FDA IND Clearance and Phase 1 Initiation of ENV-6946, a First-in-Class Oral “Multi-Biologic in a Pill” for Inflammatory ...

Enveda, a multi-asset clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life’s chemistry, today announced that the US ...
The Manila Times

D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

D3 Bio, a global clinical‑stage biotechnology company focused on developing transformative oncology therapeutics, today ...